Mixture-of-Recursions (MoR) is a new AI architecture that promises to cut LLM inference costs and memory use without ...

With capital drying up and market tailwinds gone, the biotech industry — including Recursion — needs to make tactical decisions.

Recursion Pharmaceuticals said on Tuesday it would lay off about 20% of its workforce as the biotech company tries to cope with an industry-wide funding crunch and the current policy uncertainty.

Recursion Pharmaceuticals plans to slash one-fifth of its workforce as it looks to streamline its operations. The clinical-stage biopharmaceutical company said Tuesday it will reduce its workforce ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connect with a previously announced streamlining of the AI biotech’s pipeline.

A direct adaptive equalizer (DAE) combined with a digital phase-locked loop (PLL) is a widely used receiver scheme for single-carrier underwater acoustic (UWA) communications. Ever since its birth, ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. | Recursion is ...

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025 ...

Recursion Pharmaceuticals stock isn't a good fit for risk-averse investors. The company remains unprofitable and is losing more money as it ramps up clinical development of several candidates.